Aims: To investigate the impact of treatment intensification (TI) on glycaemic outcomes in patients with type 2 diabetes with glycated haemoglobin A 1c (A1C) ≥7% after ≥6 months of treatment with 2 oral antidiabetes drugs (OADs) or basal insulin (BI). Results: A total of 3990/28 123 (14.2%) and 10 425/16 140 (65%) of eligible adults in the OAD and BI cohorts, respectively, underwent TI. These patients showed greater adjusted A1C change vs NTI patients (OAD cohort: −0.59% vs −0.25%; BI cohort: −0.30% vs −0.16%; P < .001 for both comparisons), but with higher hypoglycaemia rates (OAD cohort: odds ratio [OR] 1.68; P < .001; BI cohort: OR: 1.23; P = .004) at follow-up.
| INTRODUC TI ON
The recommended approach to the management of type 2 diabetes (T2D) for newly diagnosed patients involves the administration of oral antidiabetes drugs (OADs) combined with exercise and dietary adjustments.
1,2 Current treatment guidelines issued by the American Diabetes Association (ADA) recommend individualized glycated haemoglobin A 1c (A1C) targets based on age, disease severity, the presence of comorbidities and other individual patient factors. 2 Guidelines suggest that patients who do not achieve their target A1C levels within 3 months of initiating monotherapy and lifestyle changes may benefit from the addition of basal insulin (BI) therapy. 1, 2 If glycaemic control is still not achieved, ADA guidelines recommend intensification of treatment by the addition of a prandial insulin or a glucagon-like peptide-1 receptor agonist (GLP-1 RA), or switching to a premixed insulin. 1 The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) guidelines also recommend intensifying with a prandial insulin, a GLP-1 RA, a sodium glucose cotransporter 2 (SGLT-2) inhibitor or a dipeptidyl peptidase-4 (DPP-4) inhibitor if target A1C levels are not reached with BI therapy. 3 However, despite the presence of clear treatment guidelines, approximately 50% of patients with T2D in the United States do not achieve optimal glycaemic control. 4 Delayed treatment adjustment or failure to intensify therapy when appropriate (described as "clinical inertia") is often associated with poor clinical outcomes among these patients. 5, 6 Clinical inertia has also been suggested to contribute to poor outcomes in patients with T2D
and results in higher healthcare utilization and associated costs. 7, 8 Factors known to drive clinical inertia involve both patients and physicians. 5, 9, 10 At the patient level, erroneous perceptions and fears about insulin therapy, poor adherence to treatment and the need for training and education, as well as the presence of comorbidities and risk of hypoglycaemia (particularly in the elderly), play a role in delaying intervention when glycaemic control is suboptimal. 5, 9, 10 Physician-related factors include lack of evidence for best practices, limited experience or time for the treatment of patients and the complexity of the currently available regimens. 5, 9, 10 The evaluation of the real-world consequences of clinical inertia in patients with T2D who are poorly controlled with OADs or BI may provide important information that can be used to improve treatment decision-making.
This retrospective analysis of a large US insurance database was conducted to determine the clinical outcomes of treatment intensification (TI) vs no treatment intensification (NTI) in patients with T2D
who are inadequately controlled on dual OAD therapy or BI therapy. The pre-intensification period was defined as the 6 months prior to the intensification date, and the follow-up period was defined as the 12 months following the intensification date ( Figure 1 ). Patients were required to be continuously enrolled in the health plan for both the pre-intensification period and the follow-up period. The control group comprised patients who did not undergo treatment intensification (NTI) ≤6 months after the index date, and an intensification date was randomly assigned to these patients based on the observed distribution of intensification dates in the TI cohort. 
| MATERIAL S AND ME THODS

| Study design and eligibility criteria
| Clinical outcomes
| Statistical analyses
Bivariate comparisons were made between the TI and NTI groups, and ordinary least squares models and logistic regression were used to adjust for confounders in A1C change and hypoglycaemia, respectively.
Key covariates in the final models included study cohort, age, gender, health plan region, pre-intensification comorbidity, preintensification diabetes-related medication use, pre-intensification diabetes-related healthcare resource utilization, pre-intensification diabetes-related costs, pre-intensification hypoglycaemia and index A1C level. Table 1 . Patients with T2D who received intensification were younger, had higher mean A1C values, were more likely to be on a commercial health insurance plan, were more likely to receive particular pre-intensification OADs, were more likely to have T2D with complications and had higher pre-intensification diabetesrelated costs during the baseline period.
| RE SULTS
| Patient demographic characteristics
| Glycaemic control
Patients in the OAD cohort who underwent TI had a greater adjusted mean reduction in A1C levels at follow-up compared with patients in the NTI group (−0.59% vs −0.25%; P < .001) ( Figure 3A ).
Patients in the BI cohort who underwent TI had a greater mean reduction in A1C levels at follow-up compared with patients in the NTI group (−0.30% vs −0.16%; P < .001) ( Figure 3B ).
| Hypoglycaemia events
The proportions of patients in the OAD cohort with reported overall and severe hypoglycaemia events were higher in the TI group than the NTI group (4.9% vs 3.2%, P < .001; 1.4% vs 0.9%, P = .005, respectively). In the adjusted analysis, the odds of hypoglycaemia were 68% higher in the TI group vs the NTI group (odds ratio [OR]
1.68, 95% confidence interval [CI] 1.41-2.01; P < .001) ( Table 2 ).
The proportions of patients in the BI cohort with reported overall and severe hypoglycaemia events were higher in the TI group than in the NTI group (6.9% vs 5.8%, P = .004; 2.6% vs 2.0%, P = .031, respectively). In the adjusted analyses, the odds of hypoglycaemia were 23% higher in the TI group vs the NTI group (OR 1.23, 95% CI 1.07-1.41; P = .004) ( Table 2 ).
| D ISCUSS I ON
Our study shows that most patients in a managed-care setting in the United States who were receiving 2 OADs, and about a third of the patients who were receiving BI, did not have their treatment intensified within 6 months of an A1C measurement of ≥7%, despite evidence of poor glycaemic control and the availability of multiple other antihyperglycaemia agents. It is not clear why patients receiving treatment with OADs were less likely to receive timely intensification compared with patients on BI. It could be speculated that for patients already receiving insulin, taking the step to increase insulin dose, or to add bolus insulin, presents less of a barrier for both patients and physicians than taking the step to initiate a first injectable therapy for patients treated with only OADs. Additionally, patients who are already on insulin are likely to be treated by an endocrinologist, whereas patients on OADs are more likely to be treated by a primary care physician, who may have less expertise in the treatment of T2D than an endocrinologist and may be less aggressive in treatment intensification. It should be noted, however, that details of treating physicians were not available for this study and were not included in the analysis.
The high rate of clinical inertia in our study is in agreement with results obtained in another insurance claims analysis in the United States.
Among more than 11 500 patients with A1C levels ≥8% after 3 months of treatment with metformin ± other OADs, 52% did not have their regimen adjusted within 12 months of evidence of poor glycaemic control. 16 Clinical inertia was even higher (approximately 65%) for older patients enrolled in Medicare Advantage who were receiving BI. Furthermore, high baseline A1C levels and higher insulin dose requirements have been shown to be independently associated with greater weight gain. 25, 26 Weight reduction is an important element of T2D management, as weight gain may contribute to patient frustration, which can have a negative impact on therapy persistence and adherence. 27 The selection of antidiabetes agents that not only improve glucose control but reduce or have a neutral effect on weight, with beneficial effects on lipids, are ideal options for managing patients with T2D.
Several reports have demonstrated the effectiveness of including a GLP-1 RA in the BI regimens of patients who do not achieve targets, where addition of a GLP-1 RA was associated with significant weight loss and a lower risk of hypoglycaemia, as well as equivalent or slightly better glycaemic control than the addition of prandial insulin. [28] [29] [30] Nevertheless, the use of GLP-1 RAs in the intensification strategies observed in our study appears to be low. Furthermore, administration of GLP-1 RA requires fewer injections and is associated with a lower rate of hospitalization and lower all-cause healthcare costs than rapid-acting insulin. 31 Nonetheless, approximately 10%
of the patients in the BI cohort had their regimens intensified with bolus insulin and only about 2% received a prescription for a GLP-1
RA. Our study thus shows that clinical practice is not completely aligned with current treatment guidelines and data from clinical trials, most likely reflecting slow adaptation to an increasing body of evidence.
As expected, TI within 6 months of the first elevated measure of A1C was associated with better glycaemic control vs NTI in both cohorts, but was associated with a higher rate of hypoglycaemia, primarily driven by basal-bolus insulin and BI dose increases.
This study is subject to a number of possible limitations. Possible Database, and only patients with sufficient A1C measures were retained for analysis. Due to the nature of claims data our study is likely to underreport hypoglycaemia, as only clinically significant events resulting in contact with a healthcare professional would be captured in data based on the ICD-9-CM/ICD-10-CM codes, moreover, the definition of severe hypoglycaemia used differed from that generally used in clinical trials which also capture data on events which required assistance. The decision to proceed to TI was based on an A1C goal of 7.0%, which may not have been recommended for all patients in this study according to the current ADA treatment guidelines.
In conclusion, the main goal of treatment of T2D is to control hyperglycaemia in order to prevent or delay disease progression, and a stepwise approach is commonly used to counteract continued suboptimal glycaemic control despite therapy. However, intensification may involve a higher risk of hypoglycaemia, which may affect compliance. In this study, we 
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